January 18, 2017 07:58 AM ESTUpdated 08:52 AM
News Briefing

Mer­ri­mack re­cruits Sanofi vet Richard Pe­ters for the top job; Ob­sE­va and Brae­burn de­tail their IPO shots

Shehla Shakoor

Managing Director

• Now that Mer­ri­mack Phar­ma­ceu­ti­cals $MACK has auc­tioned off its sole com­mer­cial drug to Ipsen and fo­cused square­ly on a set of top clin­i­cal can­di­dates …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times